

Recommendations regarding ongoing communication of treatment-related infertility risk and fertility preservation in patients with CAYA cancer 2020

	Healthcare providers should:
General	Be familiar with the latest evidence-based recommendations, institutional
	policies and professional educational resources on infertility risk and
	fertility preservation procedures
	 Maintain currency with training where appropriate
	(strong recommendation; very low- to moderate-quality evidence)
	Healthcare providers should:
Provision of information about treatment- related infertility risk and fertility preservation	
	Deliver clear, comprehensive and age-appropriate information in a preference and empathetic memory
	professional, neutral and empathetic manner;
	Provide up-to-date written and/or online educational resources to
	patients and their parents/caregivers/partner in appropriate languages
	and health literacy levels.
	(strong recommendation; very low- to moderate-quality evidence)
Communicating treatment-	Healthcare providers ¹ should:
	 Involve patients and/or their parents/caregivers/partners
	Offer a private conversation with the patient depending on age
	Offer a separate conversation with parents/caregivers/partners after
	consent or assent of the patient
	• Consider the patient's age, developmental status and the family's
	cultural/religious beliefs
	Provide emotional support to patients and their
	parents/caregivers/partners during counselling about treatment-related
	infertility risk and fertility preservation and prompt psychosocial specialist
	referrals (e.g. social workers and psychologists) as appropriate
related infertility	 Initiate counselling as early as possible after a cancer diagnosis and
risk and fertility	treatment plan are established and when a change in disease status
preservation	occurs that requires treatment intensification with gonadal toxic
	agents/modalities
	Offer counselling on an ongoing basis during treatment and throughout
	survivorship because the infertility risk or patient's ideas may change
	(strong recommendation; very low- to moderate-quality evidence)
	Hospitals should:
	Establish referral pathways for accessing fertility specialists or fertility
	specialist centres where appropriate
	(strong recommendation; very low- to moderate-quality evidence)

¹ A system should be in place to identify who is responsible for having the discussion, taking into account the provider's knowledge, patient's disease state and local access to fertility specialists.

Recommendations regarding ethical issues about treatment-related infertility risk and fertility preservation in patients with CAYA cancer patients

What are the ethical issues related to fertility preservation?

Healthcare providers should:

- Foster the <u>autonomy</u> of the patient
- Assess the <u>patient's emotional</u>, <u>psychological and intellectual status</u> as part of the informed consent process
- Ensure that <u>decisions</u> about fertility preservation are <u>driven by patient's best interest</u> and not by own interest and/or interest of parents/caregivers/partners
- <u>Encourage patients to consider the risks, and the medical, social and ethical contingencies</u> of fertility preservation procedures as well as future use of frozen tissue
- Address the <u>uncertainty of future technologies</u> during counselling about infertility risk and fertility preservation procedures
- Include <u>societal and ethical values connected to social parenthood (adoption)</u> and the potential discrimination when applying for adoption in the discussions with the patient and parents/caregivers/partners about adoption
- Include a <u>two-stage consent process</u> with patients and/or their families/caregivers/partners:

 at diagnosis when the decision about harvesting and storing tissue is made and 2) after therapy at a developmentally appropriate age when the decision of whether and how to use the stored material is made
- Be aware of the importance to determine upfront with patients and their families/caregivers/partners the <u>access of researchers to their stored gametes</u>
- Be aware of the importance to determine upfront with patients and their families/caregivers/partners the <u>disposition of gametes and/or preserved tissue</u> in the event of patient's death
- Be aware of possible <u>conflicts of interest</u> between the needs of patients/parents/caregivers and the potential short- and long-term financial <u>costs</u> involved in fertility preservation procedures and storage, as well as post-treatment costs associated with pursuing familybuilding

(Good practice statements)

Publication

Mulder RL, Font-Gonzalez A, van Dulmen-den Broeder E, Quinn GP, Ginsberg JP, Loeffen EAH, Hudson MM, Burns KC, van Santen HM, Berger C, Diesch T, Dirksen U, Giwercman A, Gracia C, Hunter SE, Kelvin JF, Klosky JL, Laven JSE, Lockart BA, Neggers SJCMM, Peate M, Phillips B, Reed DR, Tinner EME, Byrne J, Veening M, van de Berg M, Verhaak CM, Anazodo A, Rodriguez-Wallberg K, van den Heuvel-Eibrink MM, Asogwa OA, Brownsdon A, Wallace WH, Green DM, Skinner R, Haupt R, Kenney LB, Levine J, van de Wetering MD, Tissing WJE, Paul NW, Kremer LCM, Inthorn J; PanCareLIFE Consortium. Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2021;22(2):e68-e80.